Replimune Group

World Rank (Jan-05-2024)

12,365

Market Cap (Jan-05-2024)

0.520 Billion USD

World Rank (Jul-30-2023)

7,950

Market Cap (Jul-30-2023)

1.172 Billion USD

World Rank (Jan-07-2022)

8,400

Market Cap (Jan-07-2022)

1.218 Billion USD

World Rank (Jan-01-2021)

5,582

Market Cap (Jan-01-2021)

1.934 Billion USD

Headquarters Country

USA

Nasdaq / NYSE Code

REPL

Market Cap (Mar-08-2026)

0.67

Employee Count

284

Employee Count as of Date

As on 2023

Headquarters City/State

Massachusetts

World Region

Americas

World Subregion

Northern America

Annual Revenue in USD

0 Million USD

Annual Net Income in USD

-118 Million USD

Annual Results for Period Ending

Mar-2022 ending year

Total Assets in USD

461 Million USD

Total Liabilities in USD

49 Million USD

Total Equity in USD

411 Million USD

Balance Sheet for Period Ending

Mar-2022 ending year

Business Sector

Company Website

Yahoo

Company Profile

Replimune Group is an emerging class of Cancer Therapeutics company that exploits the ability of viruses to selectively replicate in and kill tumors while at the same time inducing a potent, patient specific, anti tumor immune response. The headquarters is in USA.

Facts About Company

Replimune Group Annual Net loss for year ending Mar-2023 was -174 million USD.

Replimune Group Annual Net loss for year ending Mar-2022 was -118 million USD.

As on 2023, Replimune Group has 284 employees.

IPO Year

2018

Stock Exchange

Frankfurt

Nasdaq

Nasdaq Sector

Health Care

Nasdaq Industry